CymaBay price target raised to $15 from $13 at JonesResearch

JonesResearch analyst Sean Kim raised the firm’s price target on CymaBay Therapeutics to $15 from $13 and keeps a Buy rating on the shares. The company provided updates on the progress of lead program seladelpar and reaffirmed expectations for the ongoing Phase 3 RESPONSE trial to report top-line data by the end of September, which will most likely achieve the study primary endpoint in support of a potential filing, the analyst tells investors in a research note.